NEW YORK – On Wednesday, BeiGene said that it has dosed the first patient in its two-arm Phase IB/II trial of a drug combination to treat metastatic breast cancer and metastatic gastroesophageal adenocarcinoma (GEA) patients.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.